Aurobindo Pharma, in a post-earnings conference call, said it sees its EBITDA margin improving to more than 21% in FY27. It said $400 million is a reasonable base assumption for the US business compared to $387 million in the fourth quarter.
Aurobindo Pharma, in a post-earnings conference call, said it sees its EBITDA margin improving to more than 21% in FY27. It said $400 million is a reasonable base assumption for the US business compared to $387 million in the fourth quarter.